GlassScriptPhysician profile
Gary Lee Starkey
NPI 1770561698
$6,236.73
in general payments reported to CMS, 2019-2025
31 companies · $945 in 2025
The $945 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $168 · 2021: $723 · 2022: $925 · 2023: $1,656 · 2024: $1,230 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,830.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,306.21 | 2019-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $950.37 | 2021-2025 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $632.10 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $492.94 | 2021-2024 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $484.96 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $475.26 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $379.36 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $212.67 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $184.34 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $113.75 | 2019-2024 | Rexulti |
| Janssen Scientific Affairs, LLC | $112.44 | 2023 | Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $110.88 | 2023 | |
| Vanda Pharmaceuticals INC. | $91.67 | 2022-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $86.44 | 2019-2025 | Trintellix |
| Allergan, INC. | $84.13 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $68.60 | 2021-2022 | |
| Axsome Therapeutics, INC. | $66.30 | 2022-2024 | Auvelity |
| Sunovion Pharmaceuticals INC. | $62.08 | 2021 | |
| Corium, LLC | $58.92 | 2022-2023 | Azstarys |
| Tris Pharma INC | $48.32 | 2019-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $36.97 | 2019 | |
| Neuronetics, INC. | $27.59 | 2020 | |
| Eisai INC. | $27.18 | 2020-2021 | |
| Harmony Biosciences LLC | $22.05 | 2025 | |
| Idorsia Pharmaceuticals US INC | $18.47 | 2023 | Quviviq |
| Biogen, INC. | $17.76 | 2024 | |
| Merck Sharp & Dohme LLC | $14.80 | 2021 | |
| Shire North American Group INC | $14.29 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.51 | 2019 | |
| Adlon Therapeutics L.P. | $12.22 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Starkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.